Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
1.460
-0.010 (-0.68%)
At close: Nov 20, 2024, 4:00 PM
1.470
+0.010 (0.68%)
After-hours: Nov 20, 2024, 7:59 PM EST

Kairos Pharma Statistics

Total Valuation

Kairos Pharma has a market cap or net worth of $18.75 million. The enterprise value is $15.67 million.

Market Cap 18.75M
Enterprise Value 15.67M

Important Dates

The last earnings date was Thursday, November 14, 2024.

Earnings Date Nov 14, 2024
Ex-Dividend Date n/a

Share Statistics

Kairos Pharma has 12.84 million shares outstanding. The number of shares has increased by 2.97% in one year.

Current Share Class 12.84M
Shares Outstanding 12.84M
Shares Change (YoY) +2.97%
Shares Change (QoQ) +3.29%
Owned by Insiders (%) 59.24%
Owned by Institutions (%) 0.10%
Float 4.06M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 5.63
P/TBV Ratio 6.11
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.84, with a Debt / Equity ratio of 0.04.

Current Ratio 2.84
Quick Ratio 1.92
Debt / Equity 0.04
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -2.63

Financial Efficiency

Return on equity (ROE) is -375.74% and return on invested capital (ROIC) is -111.98%.

Return on Equity (ROE) -375.74%
Return on Assets (ROA) -41.71%
Return on Capital (ROIC) -111.98%
Revenue Per Employee n/a
Profits Per Employee -$913,667
Employee Count 3
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

Beta (5Y) n/a
52-Week Price Change n/a
50-Day Moving Average n/a
200-Day Moving Average n/a
Relative Strength Index (RSI) 44.96
Average Volume (20 Days) 717,971

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -1.99M
Pretax Income -812,000
Net Income -2.74M
EBITDA -1.83M
EBIT -1.99M
Earnings Per Share (EPS) -$0.26
Full Income Statement

Balance Sheet

The company has $3.22 million in cash and $142,000 in debt, giving a net cash position of $3.08 million or $0.24 per share.

Cash & Cash Equivalents 3.22M
Total Debt 142,000
Net Cash 3.08M
Net Cash Per Share $0.24
Equity (Book Value) 3.33M
Book Value Per Share 0.26
Working Capital 3.07M
Full Balance Sheet

Cash Flow

Operating Cash Flow -2.09M
Capital Expenditures n/a
Free Cash Flow -2.09M
FCF Per Share -$0.16
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Kairos Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -2.97%
Shareholder Yield -2.97%
Earnings Yield -14.62%
FCF Yield -11.13%

Analyst Forecast

The average price target for Kairos Pharma is $9.00, which is 516.44% higher than the current price. The consensus rating is "Strong Buy".

Price Target $9.00
Price Target Difference 516.44%
Analyst Consensus Strong Buy
Analyst Count 1
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 2